<i id='473CDA15A4'><strike id='473CDA15A4'><tt id='473CDA15A4'><pre id='473CDA15A4'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Virginia high school admissions case could be legal follow 
Scientists uncover potential path to treating deadly childhood tumor 
New air purifier tech could be key to improving indoor air quality 
The story of mRNA: From a loose idea to a tool that may help curb Covid 
Walensky prepares to leave CDC — and Congress — behind 
Bird flu in dairy cattle: New measures to control spread to humans 
Guidelines to prevent youth baseball injuries need more muscle 
First Opinion on colorectal cancer screening: letter and response 
State Dept. review finds Biden bears some blame for Afghanistan failures 
Bird flu reported in person exposed to presumably infected cattle 
Hepatitis C has a cure — but many Americans still lack access to it 
In areas with more Black doctors, Black people live longer 
Tori Bowie and the unacceptable rates of Black maternal death 
STAT's guide to the next generation of CAR 
Moonlake's readout produced a cash windfall. Risks remain 
